Related references
Note: Only part of the references are listed.A Neuropilin-1 Antagonist Exerts Antitumor Immunity by Inhibiting the Suppressive Function of Intratumoral Regulatory T Cells
Keunok Jung et al.
CANCER IMMUNOLOGY RESEARCH (2020)
Diverse Mechanisms of BRAF Inhibitor Resistance in Melanoma Identified in Clinical and Preclinical Studies
Stephen A. Luebker et al.
FRONTIERS IN ONCOLOGY (2019)
The Role of BRAF-Targeted Therapy for Advanced Melanoma in the Immunotherapy Era
Vito Vanella et al.
CURRENT ONCOLOGY REPORTS (2019)
Regulation of antitumour CD8 T-cell immunity and checkpoint blockade immunotherapy by Neuropilin-1
Marine Leclerc et al.
NATURE COMMUNICATIONS (2019)
Dual-targeting of EGFR and Neuropilin-1 attenuates resistance to EGFR-targeted antibody therapy in KRAS-mutant non-small cell lung cancer
Ye-Jin Kim et al.
CANCER LETTERS (2019)
A DNA Aptamer Targeting Galectin-1 as a Novel Immunotherapeutic Strategy for Lung Cancer
Yao-Tsung Tsai et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2019)
Role of Galectins in Tumors and in Clinical Immunotherapy
Feng-Cheng Chou et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Galectin Targeted Therapy in Oncology: Current Knowledge and Perspectives
Kamil Wdowiak et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
VEGF pathway-targeting drugs induce evasive adaptation by activation of neuropilin-1/cMet in colon cancer cells
Chisato Tomida et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2018)
Neuropilin-1 upregulation elicits adaptive resistance to oncogene-targeted therapies
Sabrina Rizzolio et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Neuropilin-1 is upregulated in the adaptive response of prostate tumors to androgen-targeted therapies and is prognostic of metastatic progression and patient mortality
B. W. C. Tse et al.
ONCOGENE (2017)
Galectin-1 inhibitors and their potential therapeutic applications: a patent review
Helen Blanchard et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2016)
Neuropilin-1 is associated with clinicopathology of gastric cancer and contributes to cell proliferation and migration as multifunctional co-receptors
Linhao Li et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2016)
Resistant mechanisms to BRAF inhibitors in melanoma
Jose Luis Manzano et al.
ANNALS OF TRANSLATIONAL MEDICINE (2016)
The Role of Galectin-1 in Cancer Progression, and Synthetic Multivalent Systems for the Study of Galectin-1
Jonathan M. Cousin et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2016)
Co-clinical assessment identifies patterns of BRAF inhibitor resistance in melanoma
Lawrence N. Kwong et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Adaptive stress signaling in targeted cancer therapy resistance
E. Pazarentzos et al.
ONCOGENE (2015)
VEGF-A/NRP1 stimulates GIPC1 and Syx complex formation to promote RhoA activation and proliferation in skin cancer cells
Ayumi Yoshida et al.
BIOLOGY OPEN (2015)
Galectin-1 induces vascular permeability through the neuropilin-1/vascular endothelial growth factor receptor-1 complex
Ming-Heng Wu et al.
ANGIOGENESIS (2014)
A new tumour suppression mechanism by p27KiP1: EGFR down-regulation mediated by JNK/c-Jun pathway inhibition
Yong Fang et al.
BIOCHEMICAL JOURNAL (2014)
Unraveling galectin-1 as a novel therapeutic target for cancer
Lucile Astorgues-Xerri et al.
CANCER TREATMENT REVIEWS (2014)
Glycan-dependent binding of galectin-1 to neuropilin-1 promotes axonal regeneration after spinal cord injury
H. R. Quinta et al.
CELL DEATH AND DIFFERENTIATION (2014)
OTX008, a selective small-molecule inhibitor of galectin-1, downregulates cancer cell proliferation, invasion and tumour angiogenesis
Lucile Astorgues-Xerri et al.
EUROPEAN JOURNAL OF CANCER (2014)
Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma
Chong Sun et al.
NATURE (2014)
Neuropilin-1 functions as a VEGFR2 co-receptor to guide developmental angiogenesis independent of ligand binding
Maria V. Gelfand et al.
ELIFE (2014)
Antitumor Agent Calixarene 0118 Targets Human Galectin-1 as an Allosteric Inhibitor of Carbohydrate Binding
Ruud P. M. Dings et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer
Zhenfeng Zhang et al.
NATURE GENETICS (2012)
Resistance to BRAF Inhibitors: Unraveling Mechanisms and Future Treatment Options
Jessie Villanueva et al.
CANCER RESEARCH (2011)
Galectin-1, a novel ligand of neuropilin-1, activates VEGFR-2 signaling and modulates the migration of vascular endothelial cells
S. H. Hsieh et al.
ONCOGENE (2008)
Galectin-1: a small protein with major functions
Isabelle Camby et al.
GLYCOBIOLOGY (2006)
The neuropilins and their role in tumorigenesis and tumor progression
N Guttmann-Raviv et al.
CANCER LETTERS (2006)
Galectins as modulators of tumour progression
FT Liu et al.
NATURE REVIEWS CANCER (2005)
Share Paper
